proglumide has been researched along with Body Weight in 20 studies
Proglumide: A drug that exerts an inhibitory effect on gastric secretion and reduces gastrointestinal motility. It is used clinically in the drug therapy of gastrointestinal ulcers.
proglumide : A racemate composed of equal amounts of (R)- and (S)-proglumide. A non-selective CCK antagonist that was used primarily for treatment of stomach ulcers, but has been replaced by newer drugs.
N(2)-benzoyl-N,N-dipropyl-alpha-glutamine : A dicarboxylic acid monoamide obtained by formal condensation of the alpha-carboxy group of N-benzoylglutamic acid with dippropylamine.
Body Weight: The mass or quantity of heaviness of an individual. It is expressed by units of pounds or kilograms.
| Excerpt | Relevance | Reference |
|---|---|---|
| "The effect of long term administration of a synthetic cholecystokinin (CCK) receptor antagonist CR1505 (loxiglumide) on pancreatitis was examined in rats after pancreatic duct ligation (PL) with an internal bile fistula." | 7.69 | Lack of effect of cholecystokinin receptor antagonist (CR1505) on recovery of experimental pancreatitis after pancreatic duct occlusion in rats. ( Funakoshi, A; Jimi, A; Mishima, Y; Miyasaka, K; Tomita, H, 1994) |
| "The effect of long term administration of a synthetic cholecystokinin (CCK) receptor antagonist CR1505 (loxiglumide) on pancreatitis was examined in rats after pancreatic duct ligation (PL) with an internal bile fistula." | 3.69 | Lack of effect of cholecystokinin receptor antagonist (CR1505) on recovery of experimental pancreatitis after pancreatic duct occlusion in rats. ( Funakoshi, A; Jimi, A; Mishima, Y; Miyasaka, K; Tomita, H, 1994) |
| "Loxiglumide at a dose of 50, 100, or 200 mg/kg body weight, or the same volume of saline, was given by an orogastric tube twice daily for 7 d (13 successive times)." | 3.69 | Effect of chronic oral administration of the CCK receptor antagonist loxiglumide on exocrine and endocrine pancreas in normal rats. ( Imoto, I; Jia, DM; Otsuki, M; Yamamoto, M, 1997) |
| "Pretreatment with lorglumide blocked the reducing effect of P." | 1.35 | Reducing effect of a Phaseolus vulgaris dry extract on food intake, body weight, and glycemia in rats. ( Bombardelli, E; Cabras, C; Carai, MA; Colombo, G; Donzelli, F; Fantini, N; Gessa, GL; Lobina, C; Morazzoni, P; Riva, A, 2009) |
| "The incidence of pancreatic cancer appeared significantly (P < 0." | 1.29 | Effect of cholecystokinin analogue caerulein and cholecystokinin antagonist lorglumide on pancreatic carcinogenesis in the rat. ( Alaggio, R; Behboo, R; Khajeturian, E; Militello, C; Pedrazzoli, S; Perasole, A; Rovati, L; Sperti, C, 1994) |
| "Rats treated with cholecystokinin developed more acidophilic atypical acinar cell nodules, adenomas and adenocarcinomas than control animals." | 1.28 | Role of cholecystokinin in dietary fat-promoted azaserine-induced pancreatic carcinogenesis in rats. ( Appel, MJ; Jansen, JB; Lamers, CB; Meijers, M; Rovati, LC; Sprij-Mooij, D; Van Garderen-Hoetmer, A; Woutersen, RA, 1992) |
| "Lorglumide was given 15 min before caerulein." | 1.28 | Effect of lorglumide (CR-1409) on pancreatic secretory and trophic response to caerulein in newborn rats. ( Folly, G; Papp, M; Varga, G, 1991) |
| "Cholecystokinin (CCK) has been shown to promote pancreatic growth and azaserine-induced pancreatic carcinogenesis in rats." | 1.28 | Role of cholecystokinin in the development of BOP-induced pancreatic lesions in hamsters. ( Jansen, JB; Lamers, CB; Meijers, M; Rovati, LC; van Garderen-Hoetmer, A; Woutersen, RA, 1990) |
| "This work investigates the effect, on the rat pancreas, of a chronic administration of bombesin in function of the dose and duration of treatment and examines whether this effect may be mediated by the release of endogenous gastrin or cholecystokinin." | 1.27 | Trophic effect of bombesin on the rat pancreas: is it mediated by the release of gastrin or cholecystokinin? ( Aprahamian, M; Hoeltzel, A; Lhoste, E; Pousse, A; Stock-Damge, C, 1985) |
| "Proglumide induced an increase in food intake in sham-operated rats confirming earlier results." | 1.27 | The effect of vagotomy on the increase in food intake induced by the cholecystokinin antagonist, proglumide. ( Davison, JS; Shillabeer, G, 1985) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 6 (30.00) | 18.7374 |
| 1990's | 11 (55.00) | 18.2507 |
| 2000's | 3 (15.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Fantini, N | 1 |
| Cabras, C | 1 |
| Lobina, C | 1 |
| Colombo, G | 1 |
| Gessa, GL | 1 |
| Riva, A | 1 |
| Donzelli, F | 1 |
| Morazzoni, P | 1 |
| Bombardelli, E | 1 |
| Carai, MA | 1 |
| Pu, HF | 1 |
| Huang, WJ | 1 |
| Tseng, WM | 1 |
| Wang, SW | 1 |
| Liu, YW | 1 |
| Doong, ML | 1 |
| Wang, PS | 1 |
| Little, TJ | 1 |
| Horowitz, M | 1 |
| Feinle-Bisset, C | 1 |
| Evrard, S | 1 |
| Hoeltzel, A | 2 |
| Aprahamian, M | 2 |
| Bernard, C | 1 |
| Mutter, D | 1 |
| Marescaux, J | 1 |
| Damgé, C | 1 |
| Tomita, H | 1 |
| Miyasaka, K | 2 |
| Jimi, A | 1 |
| Mishima, Y | 1 |
| Funakoshi, A | 2 |
| Sperti, C | 1 |
| Militello, C | 1 |
| Rovati, L | 1 |
| Behboo, R | 1 |
| Khajeturian, E | 1 |
| Perasole, A | 1 |
| Alaggio, R | 1 |
| Pedrazzoli, S | 1 |
| Watanapa, P | 1 |
| Flaks, B | 1 |
| Oztas, H | 1 |
| Deprez, PH | 1 |
| Calam, J | 1 |
| Williamson, RC | 1 |
| Sazaki, N | 1 |
| Matsumoto, M | 1 |
| Imoto, I | 1 |
| Yamamoto, M | 1 |
| Jia, DM | 1 |
| Otsuki, M | 1 |
| Meereis-Schwanke, K | 1 |
| Klonowski-Stumpe, H | 1 |
| Herberg, L | 1 |
| Niederau, C | 1 |
| Appel, MJ | 1 |
| Meijers, M | 3 |
| Van Garderen-Hoetmer, A | 3 |
| Lamers, CB | 4 |
| Rovati, LC | 4 |
| Sprij-Mooij, D | 1 |
| Jansen, JB | 4 |
| Woutersen, RA | 4 |
| Papp, M | 3 |
| Varga, G | 3 |
| Folly, G | 1 |
| Lhoste, E | 1 |
| Pousse, A | 1 |
| Stock-Damge, C | 1 |
| Scarpignato, C | 2 |
| Dobronyi, I | 1 |
| Douglas, BR | 1 |
| Beauchamp, RD | 1 |
| Townsend, CM | 1 |
| Singh, P | 1 |
| Glass, EJ | 1 |
| Thompson, JC | 1 |
| Shillabeer, G | 1 |
| Davison, JS | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Randomized Controlled Trial to Evaluate the Effects of Repeated Periods of Modified Fasting to Support Healthy Natural Weight Management and Prevention of Weight Gain in Overweight But Generally Healthy Adults Over the Winter Holiday Period[NCT03372109] | 23 participants (Actual) | Interventional | 2017-11-14 | Completed | |||
| The Risk Factors of Symptomatic Gallbladder Stone: Age-Sex Matched Case-control Study Performed in Single Institute[NCT02808546] | 342 participants (Actual) | Observational | 2009-01-31 | Completed | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
1 review available for proglumide and Body Weight
| Article | Year |
|---|---|
Role of cholecystokinin in appetite control and body weight regulation.
Topics: Animals; Appetite; Body Weight; Cholecystokinin; Digestive System Physiological Phenomena; Energy In | 2005 |
19 other studies available for proglumide and Body Weight
| Article | Year |
|---|---|
Reducing effect of a Phaseolus vulgaris dry extract on food intake, body weight, and glycemia in rats.
Topics: alpha-Amylases; Animals; Blood Glucose; Body Weight; Cholecystokinin; Drug Interactions; Eating; Ene | 2009 |
Effects of juice from Morinda citrifolia (Noni) on gastric emptying in male rats.
Topics: Animals; Beverages; Body Weight; Cholecystokinin; Drinking; Eating; Gastric Emptying; Gastrointestin | 2004 |
Implication of cholecystokinin in pancreatic adaptation after biliopancreatic bypass in the rat.
Topics: Adaptation, Physiological; Animals; Biliopancreatic Diversion; Body Weight; Cholecystokinin; Data In | 1994 |
Lack of effect of cholecystokinin receptor antagonist (CR1505) on recovery of experimental pancreatitis after pancreatic duct occlusion in rats.
Topics: Animals; Body Weight; Cholecystokinin; Duodenum; Eating; Intestinal Mucosa; Ligation; Male; Organ Si | 1994 |
Effect of cholecystokinin analogue caerulein and cholecystokinin antagonist lorglumide on pancreatic carcinogenesis in the rat.
Topics: 9,10-Dimethyl-1,2-benzanthracene; Adenocarcinoma; Animals; Body Weight; Ceruletide; Chi-Square Distr | 1994 |
Inhibitory effect of a cholecystokinin antagonist on pancreatic carcinogenesis after pancreatobiliary diversion.
Topics: Animals; Azaserine; Biliopancreatic Diversion; Body Weight; Cholecystokinin; Cocarcinogenesis; Male; | 1993 |
Effects of intraduodenal administration of a low dose of cholecystokinin (CCK) antagonist (CR-1505) on plasma CCK concentration, intestinal CCK content, and levels of CCK mRNA.
Topics: Animals; Base Sequence; Body Weight; Cholecystokinin; Drug Administration Routes; Gene Expression; H | 1995 |
Effect of chronic oral administration of the CCK receptor antagonist loxiglumide on exocrine and endocrine pancreas in normal rats.
Topics: Administration, Oral; Animals; Body Weight; DNA; Dose-Response Relationship, Drug; Hormone Antagonis | 1997 |
Long-term effects of CCK-agonist and -antagonist on food intake and body weight in Zucker lean and obese rats.
Topics: Animals; Body Weight; Ceruletide; Cholecystokinin; Drug Resistance; Eating; Female; Male; Obesity; O | 1998 |
Role of cholecystokinin in dietary fat-promoted azaserine-induced pancreatic carcinogenesis in rats.
Topics: Animals; Azaserine; Body Weight; Cholecystokinin; Dietary Fats; Liver; Male; Organ Size; Pancreas; P | 1992 |
Effect of lorglumide (CR-1409) on pancreatic secretory and trophic response to caerulein in newborn rats.
Topics: Amylases; Animals; Animals, Newborn; Body Weight; Ceruletide; Cholecystokinin; Corticosterone; Femal | 1991 |
Effects of bombesin on the development of N-nitrosobis(2-oxopropyl)amine-induced pancreatic lesions in hamsters.
Topics: Animals; Body Weight; Bombesin; Cholecystokinin; Cricetinae; Liver; Male; Mesocricetus; Nitrosamines | 1991 |
Role of cholecystokinin in the development of BOP-induced pancreatic lesions in hamsters.
Topics: Animals; Body Weight; Carcinogens; Cholecystokinin; Cocarcinogenesis; Cricetinae; Male; Nitrosamines | 1990 |
Trophic effect of bombesin on the rat pancreas: is it mediated by the release of gastrin or cholecystokinin?
Topics: Amylases; Animals; Body Weight; Bombesin; Cholecystokinin; Chymotrypsin; Gastrectomy; Gastrins; Lipa | 1985 |
Effect of a new potent CCK antagonist, lorglumide, on caerulein- and bombesin-induced pancreatic secretion and growth in the rat.
Topics: Amylases; Anesthesia; Animals; Body Weight; Bombesin; Ceruletide; Cholecystokinin; DNA; Glutamine; I | 1989 |
Pancreatic secretory and trophic response to caerulein in rats: effect of proglumide and lorglumide.
Topics: Amylases; Animals; Body Weight; Ceruletide; DNA; Glutamine; In Vitro Techniques; Organ Size; Pancrea | 1989 |
Study into the role of cholecystokinin in bombesin-stimulated pancreatic growth in rats and hamsters.
Topics: Animals; Body Weight; Bombesin; Cholecystokinin; Cricetinae; DNA; Male; Mesocricetus; Pancreas; Prog | 1989 |
Proglumide, a gastrin receptor antagonist, inhibits growth of colon cancer and enhances survival in mice.
Topics: Adenocarcinoma; Animals; Body Weight; Cell Division; Cell Line; Colon; Colonic Neoplasms; Gastric Fu | 1985 |
The effect of vagotomy on the increase in food intake induced by the cholecystokinin antagonist, proglumide.
Topics: Animals; Appetite; Body Weight; Cholecystokinin; Energy Intake; Glutamine; Male; Proglumide; Rats; R | 1985 |